NDAINTRAVENOUSSOLUTION
Approved
Oct 2022
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
3/8 — Basic
NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE (norepinephrine bitartrate) by Infinant Health is (alpha-adrenergic action) and an inotropic stimulator of the heart and dilator of coronary arteries (beta-adrenergic action). First approved in 2022.
Drug data last refreshed 9h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Norepinephrine bitartrate in 0.9% sodium chloride is an intravenous catecholamine indicated for acute hypotension and cardiogenic shock in critical care settings. It works through dual alpha-adrenergic vasoconstriction and beta-adrenergic inotropic and coronary vasodilatory effects. This formulation was approved in October 2022 as an NDA by Infinant Health.
Peak11.6 years to LOE
Product is in peak commercial phase with established market presence; brand teams are likely focused on market penetration and defending against potential generics.
Mechanism of Action
(alpha-adrenergic action) and an inotropic stimulator of the heart and dilator of coronary arteries (beta-adrenergic action).
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
This critical care product offers stable career opportunities in hospital-based commercial roles, where success depends on healthcare provider relationships and supply chain partnerships rather than consumer marketing. Long patent protection and peak lifecycle status suggest sustained, predictable team structures without imminent restructuring.
Hospital Account ManagerICU Segment Specialist
Worked on NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE at Infinant Health? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.